Diageo plc vs Zoetis Inc — how do they compare? Diageo plc trades at $94.95 (market cap $53.05B), while Zoetis Inc trades at $73.63 (market cap $31.14B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| DEO | ZTS | |
|---|---|---|
Market Cap | $53.05B | $31.14B |
Sector | Technology | Health |
52-Week High | $115.33 | $156.76 |
52-Week Low | $72.47 | $71.91 |
Enterprise Value | $72.54B | $38.70B |
Dividend Yield | 3.5% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.47, down 3.75% on the day, amid mixed earnings and a $1 billion cost-cutting plan announced in August 2026. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentals reveal a P/E of 30.47, net income margin of 8.84%, and recent earnings beats in Q4 2025 and Q2 2026, offset by a Q2 2025 miss. Revenue dipped to $19.6 billion in 2026, with North America weakness pressuring results.
The outlook is cautiously optimistic, driven by cost savings and strategic shifts under CEO Dave Lewis, but risks include regional sales volatility and high debt. Analyst consensus leans buy (48.65%), with price targets suggesting upside, though execution on the turnaround plan is critical for sustained growth.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →